10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-Factor X LC Antibody
Rabbit polyclonal antibody to Factor X LC
Catalog # AP61042

Specification

Anti-Factor X LC Antibody - Product Information

Application	**WB**
Primary Accession	P00742
Other Accession	O88947
Reactivity	**Human, Mouse, Rat**
Host	**Rabbit**
Clonality	**Polyclonal**
Calculated MW	**54732**

Anti-Factor X LC Antibody - Additional Information

Gene ID 2159

Other Names
Coagulation factor X; Stuart factor; Stuart-Prower factor

Target/Specificity
KLH-conjugated synthetic peptide encompassing a sequence within the N-term region of human Factor X LC. The exact sequence is proprietary.

Dilution
WB~~WB (1/500 - 1/1000)

Format
Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.09% (W/V) sodium azide.

Storage
Store at -20 °C.Stable for 12 months from date of receipt

Anti-Factor X LC Antibody - Protein Information

Name F10

Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting (PubMed:22409427). Factor Xa activates pro-inflammatory signaling pathways in a protease-activated receptor (PAR)-dependent manner (PubMed:24041930, PubMed:30568593, PubMed:34831181, PubMed:<a href="http://www.uniprot.org/citations/18202198"

target="_blank">18202198). Up-regulates expression of protease- activated receptors (PARs) F2R, F2RL1 and F2RL2 in dermal microvascular endothelial cells (PubMed:35738824). Triggers the production of pro- inflammatory cytokines, such as MCP-1/CCL2 and IL6, in cardiac fibroblasts and umbilical vein endothelial cells in PAR-1/F2R-dependent manner (PubMed:30568593, PubMed:34831181). Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2, IL6, TNF-alpha/TNF, IL- 1beta/IL1B, IL8/CXCL8 and IL18, in endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824, PubMed:9780208). Induces expression of adhesion molecules, such as ICAM1, VCAM1 and SELE, in endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824, PubMed:9780208). Increases expression of phosphorylated ERK1/2 in dermal microvascular endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824). Triggers activation of the transcription factor NF-kappa-B in dermal microvascular endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824). Activates pro-inflammatory and pro-fibrotic responses in dermal fibroblasts and enhances wound healing probably via PAR-2/F2RL1-dependent mechanism (PubMed:18202198). Activates barrier protective signaling responses in endothelial cells in PAR-2/F2RL1-dependent manner; the activity depends on the cleavage of PAR-2/F2RL1 by factor Xa (PubMed:22409427). Up-regulates expression of plasminogen activator inhibitor 1 (SERPINE1) in atrial tissues (PubMed:24041930).

Cellular Location
Secreted.

Tissue Location
Plasma; synthesized in the liver.

Anti-Factor X LC Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Anti-Factor X LC Antibody - Images

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999



Western blot analysis of Factor X LC expression in HepG2 (A), HEK293T (B), PC3 (C), AML12 (D), PC12 (E) whole cell lysates.

Anti-Factor X LC Antibody - Background

KLH-conjugated synthetic peptide encompassing a sequence within the N-term region of human Factor X LC. The exact sequence is proprietary.